 | 
 | |
John C. Burnett, M.D., Ph.D.
Chairman
Dr. Burnett is a co-inventor of CD-NP and the Chairman of Nile’s Scientific Advisory Board. He is a Professor of Medicine and Physiology at the Mayo Clinic College of Medicine, where he is also the Head of the Cardiorenal Research Laboratory. Dr. Burnett's current work focuses on cardiovascular endocrinology of heart failure and atherosclerosis. The Cardiorenal Research Laboratory has pursued the broad area of cardiovascular endocrinology, with a focus on humoral mechanisms which link the heart, vascular wall and kidney in heart failure and atherosclerosis. Humoral systems of interest include the natriuretic peptides (ANP, BNP, CNP, and DNP), endothelin, angiotensin II, aldosterone and adrenomedullin. His studies have also focused on defining such humoral systems as noninvasive markers for these disease processes as well as prognostic factors in predicting outcome. Work in the laboratory employs methodologies of integrative physiology, cell and molecular biology, biochemistry and human investigation. Research also focuses on strategies for the treatment of CHF, including the use of novel natriuretic peptides.
Michel Komajda, M.D.
Dr. Komajda is a Professor of Cardiology in the Department of Cardiology at University Pierre et Marie Curie and Pitie Salpetriere Hospital in France. In service of the European Society of Cardiology (ESC), he is the Vice President of Associations, Working Groups, Councils from 2006 to 2008. He is also currently a Team Leader for INSERM Research Unit 621 "Genetique, Physiopathologie et Pharmacologie du Remodelage Cardiovasculaire". He was the Chairman of the ESC's Heart Failure working group from 2001-2002, and member of the writing committee for the ESC's "Chronic Heart Failure Guidelines" from 2001 to 2005. He was a Board Member of the French Society of Cardiology from 1991-2006, serving as the President from 2002-2003. He has been on the steering committee for many major cardiovascular trials through out his career; most recently CARMEN, COMET, I-PRESERVE, HEAAL, SHIFT, and RECORD. He has also published numerous articles that have contributed to the advancement of the treatment of heart failure.
Douglas Mann, M.D.
Dr. Mann is the Don W. Chapman Chair and Professor of Medicine and Molecular Physiology and Biophysics at Baylor College of Medicine, Chief of Cardiology at Baylor College of Medicine, St. Luke’s Episcopal Hospital and the Texas Heart Institute, and Director of the Winters Center for Heart Failure Research. His research interests have focused on the basic cellular and molecular mechanisms that lead to cardiac decompensation, including the role that inflammatory mediators play in regulating cardiac structure and function. Dr. Mann is a member of the American Society for Clinical Investigation, the Association of University Cardiologists, the Heart Failure Society of America, the International Cytokine Society, the International Society for Heart Failure Research and is a Fellow of the American College of Cardiology as well as the American College of Chest Physicians. He is a member of the Editorial Board of Circulation, The Journal of Cardiac Failure, Heart and Vessels, Heart Failure Reviews, Heart Failure Monitor and Cardiology Today. Dr. Mann has published numerous articles peer reviewed articles on the role on inflammatory mediators in heart failure, and the molecular and cellular basis for cardiac dysfunction and remodeling. He has received numerous awards including the Alfred Soffer Award for Editorial Excellence from the American College of Chest Physicians, the Michael E. Debakey award for Excellence in research.
Barry M. Massie, M.D.
Barry M. Massie, MD is a Professor of Medicine at the University of California in San Francisco and Chief of the Cardiology Division at the San Francisco VAMC. He is a nationally and internationally recognized researcher and authority in the field of heart failure. Dr. Massie was the Principal Investigator of the Warfarin and Antiplatelet Trial in Chronic Heart Failure (WATCH), a multicenter, multinational trial being conducted under the auspices of the VA Cooperative Study Program. He is also the Principal Investigator of the ongoing I-Preserve trial, the largest study of the treatment of patients with heart failure and preserved ejection fraction. He serves on the steering committee or DSMB of 6 other ongoing trials, including two major NHLBI studies. He also has several grants in the areas of health services and outcomes research. In addition to his research and clinical work, Dr. Massie is a founding member of the Heart Failure Society of America, and was Program Chairman for the HFSA 2001 and 2002 annual scientific meetings. He had served on the Program Committees of the American College of Cardiology and the European Society of Cardiology. He is the Editor-in-Chief of the Journal of Cardiac Failure, as well as serving on the editorial boards of numerous journals. He was a member of the Heart Failure Guideline Panel of the Agency for Health Care Policy and Research and has also served on the Guideline Committee of the Heart Failure Society. He remains a consultant to the Food and Drug Administration, after serving as a member and Chairman of its Cardio-Renal Advisory Panel.
John J. V. McMurray, M.D.
Dr. John McMurray is a Professor of Medical Cardiology and an Honorary Consultant Cardiologist at the University of Glasgow in Scotland, where he is the leader of the Heart Failure Research Group. The research group’s primary interests include the epidemiology, vascular pathophysiology, clinical pharmacology, clinical trials and multidisciplinary management of chronic heart failure. Dr. McMurray is a member of the Board of the Heart Failure Association of the European Society of Cardiology, and has served on the Executive or Steering Committees for several large, randomized trials in heart failure/left ventricular dysfunction, coronary heart disease, diabetes renal failure and other disease areas. Dr. McMurray is a member of the editorial board of several international journals focusing on cardiology and heart failure.
James B. Young, M.D.
Dr. James Young is Chairman, Division of Medicine at the Cleveland Clinic Foundation; Professor of Medicine and Academic Chairman of the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; and a Medical Director of the Cleveland Clinic Kaufman Center for Heart Failure. He holds the George and Linda Kaufman Chair and is the newly named Study Chairman of the NIH, FDA, and CMS Interagency Registry for Mechanical Assist Circulatory Support (INTERMACS). He has a joint appointment to the Multi-organ Transplant Center. Dr. Young is board certified as a Diplomat of the American Board of Internal Medicine as well as the subspecialty of Cardiovascular Disease. Dr. Young’s clinical research activities have focused on heart failure and cardiac transplant therapeutics including early experiences with dopamine receptor agonists, angiotensin-converting enzyme inhibitors, beta blockers, calcium channel blockers, angiotensin receptor blockers, immunosuppressants, and a variety of parenteral inotropes and vasodilators. He has published almost 500 manuscripts and abstracts and several textbooks.
| |
|
